Findings covered by feature article in national newspaper VG: A versatile Fc technology broadly applicable in antibody design aiming for long-acting prophylactic or therapeutic interventions

In a paper published in Nature Communcations, the laboratory of Professor Jan Terje Andersen and collaborators report on a novel antibody constant region (Fc) variant that is designed to give antibodies broad biodistribution and make them long-acting in the body. These features allow the antibodies to reach the site of action at high concentrations, and the improvements in pharmacokinetics are expected to increase patient convenience, treatment adherence and reduce costs for the healthcare system. This is particularly important for treatment of life-long chronic diseases and for prophylactic treatment of severe infections.

The findings have been covered by several media outlets, including the major Norwegian newspaper VG.